Cameron McDonough
Chief Executive Officer chez GENERATION BIO CO.
Fortune : 7 M $ au 31/03/2024
Profil
Cameron Geoffrey McDonough is the founder of Catalyst Medical Solutions, Inc. He currently holds the position of President, Chief Executive Officer & Director at Generation Bio Co. since 2017, Director at Third Harmonic Bio, Inc. since 2024, and Advisor at Atlas Venture Advisors, Inc. Additionally, he has previously worked as President & Chief Executive Officer at Swedish Orphan Biovitrum AB from 2011 to 2017, Independent Director at PTC Therapeutics, Inc. from 2013 to 2017, Independent Director at Zafgen, Inc., Independent Non-Executive Director at Surface Oncology, Inc. from 2018 to 2022, and President-Europe, Middle East & Africa Region at Genzyme Corp.
from 2002 to 2011.
He obtained his undergraduate degree from The University of North Carolina at Chapel Hill and his graduate degree from Harvard Medical School in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENERATION BIO CO.
2,75% | 15/04/2024 | 1 824 920 ( 2,75% ) | 7 M $ | 31/03/2024 |
THIRD HARMONIC BIO, INC.
-.--% | 27/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Cameron McDonough
| Sociétés | Poste | Début |
|---|---|---|
| GENERATION BIO CO. | Chief Executive Officer | 01/10/2017 |
| THIRD HARMONIC BIO, INC. | Director/Board Member | 28/03/2024 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Cameron McDonough
| Sociétés | Poste | Fin |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Director/Board Member | 28/02/2022 |
| PTC THERAPEUTICS, INC. | Director/Board Member | 18/09/2017 |
| SWEDISH ORPHAN BIOVITRUM AB | Chief Executive Officer | 22/05/2017 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| Catalyst Medical Solutions, Inc. | Founder | - |
Formation de Cameron McDonough
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| GENERATION BIO CO. | Health Technology |
| THIRD HARMONIC BIO, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
| Catalyst Medical Solutions, Inc. |
